Revolution Medicines, Inc. (NASDAQ:RVMD) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET
Company Participants
David Arrington - SVP of IR and Corporate Affairs
Mark Goldsmith - Chairman and CEO
Jack Anders - SVP, Finance and Principal Accounting Officer
Steve Kelsey - President, Research and Development
Conference Call Participants
Marc Frahm - Cowen & Company
Alec Stranahan - Bank of America
Jonathan Chang - SVB Securities
Neil Carnahan - Stifel
Noah Eisenberg - JPMorgan Chase
Operator
Good day. My name is Christie, and I'll be your conference facilitator today. Welcome to the Revolution Medicines Second Quarter 2022 Earnings Conference Call. Today's call is being recorded. [Operator Instructions]
I would now like to hand the conference over to David Arrington, Revolution Medicines' SVP of Investor Relations and Corporate Affairs for opening remarks. David, you may begin.
David Arrington
Thank you, and welcome, everyone, to our second quarter earnings call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicines' Chairman and Chief Executive Officer; Dr. Steve Kelsey, the Company's President, Research and Development; and Jack Anders, our SVP of Finance and Principal Accounting Officer.
As we begin, I would like to note that our presentation will include statements regarding the current beliefs of the company with respect to our business that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are subject to a number of assumptions, risks and uncertainties. Actual results may differ materially from these statements, and except as required by law, the company undertakes no obligation to revise or update any forward-looking statements. I encourage you to review the legal disclaimer slide of our corporate presentation or the earnings press release as well as all of the company's filings with the SEC concerning these and other matters.
With that, I will turn the call over to Dr. Mark Goldsmith, Revolution Medicines' Chairman and Chief Executive Officer. Mark?
Mark Goldsmith
Good afternoon, and thank you for joining us.
Today, I'll provide an update on our corporate progress and our Senior Vice President of Finance, Jack Anders will provide highlights of our financial results.
In the second quarter of 2022, Revolution Medicines continued building strong momentum in the discovery and development of innovative medicines on behalf of patients with a wide range of RAS-addicted cancers, which represent 30% of all human cancers. We are advancing a deep and cohesive portfolio of RAS targeted therapeutics, led by our development stage RAS (ON) Inhibitors. Recently, we reported significant progress across our pipeline, setting us up for an exciting period as our assets progress over the next 12 to 18 months.